Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eluforsen - ProQR Therapeutics

Drug Profile

Eluforsen - ProQR Therapeutics

Alternative Names: QR 10; QR-010

Latest Information Update: 20 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProQR Therapeutics
  • Class Antifibrotics; Oligoribonucleotides
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 17 Aug 2018 Eluforsen is still in phase I development for Cystic fibrosis in Belgium, Canada, Czech Republic, Denmark, France, Germany, Italy, the US and the UK (Inhalation, Aerosol) (NCT02532764)
  • 17 Aug 2018 ProQR Therapeutics completes a phase Ib trial in Cystic fibrosis in Belgium, Canada, Czech Republic, Denmark, France, Germany, Italy, Spain, the US and the UK (Inhalation, Aerosol) (ProQR Therapeutics pipeline, August 2018), prior August 2018
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Cystic-fibrosis in Belgium (Inhalation, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top